Orexo has announced that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV, Orexo’s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder.
The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company´s intellectual property for ZUBSOLV in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV.
“With this new patent we stand even stronger and are well positioned to continue to play an important role in helping patients suffering from opioid addiction,”
“I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new innovative products to the benefit of patients and society. We continue to obtain strong patent protection of our products, and the quality of our patents was demonstrated in 2018 by the US Court of Appeals for the Federal Circuit when one of our ZUBSOLV patents was found valid and infringed by a generic company. With this new patent we stand even stronger and are well positioned to continue to play an important role in helping patients suffering from opioid addiction,” says Nikolaj Sørensen, President and CEO, Orexo.
Photo of Nikolaj Sorensen: Jenny Öhman/Nordic Life Science